Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,556 | 405 | 3,101 |
| Samples | 780 | 146 | 626 |
| Peptides | 611 | 101 | 528 |
Function
ATP2B3 · ATPase plasma membrane Ca2+ transporting 3
The protein encoded by this gene belongs to the family of P-type primary ion transport ATPases characterized by the formation of an aspartyl phosphate intermediate during the reaction cycle. These enzymes remove bivalent calcium ions from eukaryotic cells against very large concentration gradients and play a critical role in intracellular calcium homeostasis. The mammalian plasma membrane calcium ATPase isoforms are encoded by at least four separate genes and the diversity of these enzymes is further increased by alternative splicing of transcripts. The expression of different isoforms and splice variants is regulated in a developmental, tissue- and cell type-specific manner, suggesting that these pumps are functionally adapted to the physiological needs of particular cells and tissues. This gene encodes the plasma membrane calcium ATPase isoform 3. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 556 amino-acid changes on canonical ENST00000263519 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ATP2B3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ATP2B3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 50/612 8% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Melanoma | 12/210 6% | 78/1899 4% |
| Non-Small Cell Lung Carcinoma | 28/304 9% | 44/1390 3% |
| Colorectal Carcinoma | 17/143 12% | 99/3239 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 23/752 3% |
| Gastric Carcinoma | 5/74 7% | 47/1809 3% |
| Other Solid Cancers | 4/94 4% | 38/1515 3% |
| Cervical Carcinoma | 3/35 9% | 8/422 2% |
| Bladder Carcinoma | 7/58 12% | 15/956 2% |
| Mesothelioma | 2/62 3% | 2/165 1% |
| Head and Neck Carcinoma | 3/85 4% | 26/1574 2% |
| Adrenocortical Carcinoma | 2/3 67% | 0/112 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 12/810 1% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Pancreatic Carcinoma | 6/89 7% | 15/1611 1% |
| Breast Carcinoma | 9/144 6% | 32/3264 1% |
| Non-Cancerous | 2/104 2% | 9/830 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 18/1592 1% |
| Other Sarcomas | 6/69 9% | 2/699 0% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Biliary Tract Carcinoma | 2/54 4% | 7/950 1% |
| Hepatocellular Carcinoma | 0/46 0% | 20/2210 1% |
| Glioma | 1/52 2% | 17/2127 1% |
| Neuroendocrine Tumour | 0/154 0% | 6/577 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 14/2550 1% |
Mutation Distribution
Where ATP2B3 is mutated · all tissues, split by cell line vs tissue
How many mutations in ATP2B3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,556 mutations in ATP2B3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|